Publication Name	World Journal of Gastroenterology
Manuscript ID	6890
Country	Czech Republic

Received	2013-10-29 19:34
Peer-Review Started	2013-10-31 18:16
To Make the First Decision	2013-12-16 17:34
Return for Revision	2014-02-18 15:24
Revised	2014-03-05 01:09
Second Decision	2014-04-16 11:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-16 12:05
Articles in Press	2014-05-23 11:03
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-04-24 03:26
Typeset the Manuscript	2014-07-14 15:51
Publish the Manuscript Online	2014-08-18 16:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
Manuscript Source	Invited Manuscript
All Author List	Beatrice Mohelnikova-Duchonova, Bohuslav Melichar and Pavel Soucek
Funding Agency and Grant Number	Funding Agency Grant Number Internal Grant Agency of the Czech Ministry of Health NT14329-3 Research project Biomedreg CZ.1.05/2.1.00/01.0030 Project from European Regional Development Fund CZ.1.05/2.1.00/03.0076 project of the Palacky University LF_2013_010
Corresponding Author	Beatrice Mohelnikova-Duchonova, MD, PhD, Department of Oncology, Palacky University Medical School and Teaching Hospital, IP Pavlova 6, 77525 Olomouc, Czech Republic. d.beatrice@seznam.cz
Key Words	Colorectal cancer; Chemotherapy; 5-Fluorouracil; Oxaliplatin; Irinotecan
Core Tip	5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) and irinotecan (FOLFIRI) represent the most effective chemotherapy regimens for colorectal carcinoma patients with distant metastases. Pharmacogenetics represents a promising strategy for the individualization of therapy, including identification of patients at increased risk of toxicity. This review summarizes contemporary knowledge about associations of gene and protein expression and genetic variability of putative biomarkers for the response of colorectal cancer to FOLFOX/FOLFIRI regimens. From the published data reviewed it is obvious that the problem is highly complex and the ultimate profile of the drug-sensitive or resistant patient will most probably be jointly defined by genetic, epigenetic, intracellular, extracellular, and extrinsic factors.
Publish Date	2014-08-18 16:49
Citation	Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330
URL	http://www.wjgnet.com/1007-9327/full/v20/i30/10316.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i30.10316

Full Article (PDF)	WJG-20-10316.pdf
Full Article (Word)	WJG-20-10316.doc
Manuscript File	6890-Review.doc
Answering Reviewers	6890-Answersing reviewers.pdf
Copyright License Agreement	6890-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6890-Language certificate.pdf
Peer-review Report	6890-Peer review.pdf
Scientific Editor Work List	6890-Scientific editor work list.doc